Bevnexxa 400mg Injection
Marketer
Celon Laboratories Ltd
Salt Composition
Bevacizumab (400mg)
Overview Bevnexxa 400mg Injection
Oncaspar 400mg Injection is a cancer treatment drug. Indicated for colorectal, non-small cell lung, renal, brain, ovarian, and cervical cancers, it inhibits tumor angiogenesis, thus hindering tumor growth. Highly effective, it's often a first-line therapy in combination with other anticancer agents, administered intravenously via infusion or port. Dosage and treatment length are determined by your physician, who will also monitor for infusion reactions like hypertension and respiratory distress. Continued use depends on disease control and manageable side effects, per your doctor's assessment. Regular blood pressure monitoring and urine protein checks may be recommended. Common side effects include rectal hemorrhage, altered taste perception, and cephalalgia. Pre-surgical notification is crucial due to its potential impact on wound healing. Increased bleeding risk necessitates immediate medical attention for any unusual bleeding episodes. Disclose pregnancy, pregnancy plans, or breastfeeding to your physician. Comprehensive disclosure of all medications to your healthcare provider is essential due to potential drug interactions.
Uses of Bevnexxa 400mg Injection
Colorectal cancer, ovarian neoplasm, cervical carcinoma, renal cell carcinoma, intracranial tumor, and non-small cell lung carcinoma.
Major Benefits of Bevnexxa 400mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Bevnexxa 400mg Injection:
- Exfoliative dermatitis
- High blood pressure
- Nosebleeds
- Protein in urine
- Decreased appetite
- Electrolyte imbalance
- Peripheral sensory neuropathy
- Breathlessness
- Thromboembolism
- Wound healing complications
- Ovarian failure
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Mucosal inflammation
- Abscess
- Cellulitis
- Hypersensitivity
- Rectovaginal fistula
How to use Bevnexxa 400mg Injection:
This medication will be administered by your physician or their qualified nurse; self-medication is strictly prohibited.
How Bevnexxa 400mg Injection works:
Xelka 400mg Injection is an angiogenesis inhibitor. Its mechanism of action involves VEGF blockade, thus preventing the development of new blood vessels supplying tumors with essential oxygen and nutrients.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Bevnexxa 400mg Injection may pose safety risks; professional medical advice is recommended.
PregnancyCONSULT YOUR DOCTOR
The use of Bevnexxa 400mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against potential dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of Bevnexxa 400mg Injection while breastfeeding is likely inadvisable. Available data from humans indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Administering Bevnexxa 400mg Injection may induce adverse reactions that could compromise driving safety. Somnolence and syncope have been observed in patients receiving Bevnexxa 400mg Injection, potentially affecting driving capabilities.
KidneySAFE IF PRESCRIBED
The use of Bevnexxa 400mg Injection in patients with kidney impairment appears to pose minimal risk. Preliminary findings indicate dose modification may be unnecessary; however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Bevnexxa 400mg Injection in patients with liver disease appears to present a low risk. Current evidence indicates dose modification of Bevnexxa 400mg Injection may be unnecessary for this population; however, physician consultation is recommended.
What if you forget to take Bevnexxa 400mg Injection :
Omit a scheduled dose of Bevnexxa 400mg Injection? Seek your physician's advice.
Facts to Know About Bevnexxa 400mg Injection
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Behavior Class | VEGF inhibitor |
3,018 People bought this recently